Development of a bispecific immune engager using a recombinant malaria protein

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Development of a bispecific immune engager using a recombinant malaria protein. / Nordmaj, Mie A.; Roberts, Morgan E.; Sachse, Emilie S.; Dagil, Robert; Andersen, Anne Poder; Skeltved, Nanna; Grunddal, Kaare V.; Erdoğan, Sayit Mahmut; Choudhary, Swati; Gustavsson, Tobias; Ørum-madsen, Maj Sofie; Moskalev, Igor; Tian, Weihua; Yang, Zhang; Clausen, Thomas M.; Theander, Thor G.; Daugaard, Mads; Nielsen, Morten A.; Salanti, Ali.

In: Cell Death & Disease, Vol. 12, No. 4, 353, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nordmaj, MA, Roberts, ME, Sachse, ES, Dagil, R, Andersen, AP, Skeltved, N, Grunddal, KV, Erdoğan, SM, Choudhary, S, Gustavsson, T, Ørum-madsen, MS, Moskalev, I, Tian, W, Yang, Z, Clausen, TM, Theander, TG, Daugaard, M, Nielsen, MA & Salanti, A 2021, 'Development of a bispecific immune engager using a recombinant malaria protein', Cell Death & Disease, vol. 12, no. 4, 353. https://doi.org/10.1038/s41419-021-03611-0

APA

Nordmaj, M. A., Roberts, M. E., Sachse, E. S., Dagil, R., Andersen, A. P., Skeltved, N., Grunddal, K. V., Erdoğan, S. M., Choudhary, S., Gustavsson, T., Ørum-madsen, M. S., Moskalev, I., Tian, W., Yang, Z., Clausen, T. M., Theander, T. G., Daugaard, M., Nielsen, M. A., & Salanti, A. (2021). Development of a bispecific immune engager using a recombinant malaria protein. Cell Death & Disease, 12(4), [353]. https://doi.org/10.1038/s41419-021-03611-0

Vancouver

Nordmaj MA, Roberts ME, Sachse ES, Dagil R, Andersen AP, Skeltved N et al. Development of a bispecific immune engager using a recombinant malaria protein. Cell Death & Disease. 2021;12(4). 353. https://doi.org/10.1038/s41419-021-03611-0

Author

Nordmaj, Mie A. ; Roberts, Morgan E. ; Sachse, Emilie S. ; Dagil, Robert ; Andersen, Anne Poder ; Skeltved, Nanna ; Grunddal, Kaare V. ; Erdoğan, Sayit Mahmut ; Choudhary, Swati ; Gustavsson, Tobias ; Ørum-madsen, Maj Sofie ; Moskalev, Igor ; Tian, Weihua ; Yang, Zhang ; Clausen, Thomas M. ; Theander, Thor G. ; Daugaard, Mads ; Nielsen, Morten A. ; Salanti, Ali. / Development of a bispecific immune engager using a recombinant malaria protein. In: Cell Death & Disease. 2021 ; Vol. 12, No. 4.

Bibtex

@article{9daac869afe94ddeaa73c92c90cc4bac,
title = "Development of a bispecific immune engager using a recombinant malaria protein",
abstract = "As an immune evasion and survival strategy, the Plasmodium falciparum malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohydrate abundantly and exclusively present in the placenta. Cancer cells were found to share the same expression of this distinct carbohydrate, termed oncofetal chondroitin sulfate on their surface. In this study we have used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. Conjugation of these two proteins resulted in a single functional moiety that induced immune mediated killing of a broad range of cancer cells in vitro and facilitated tumor arrest in an orthotopic bladder cancer xenograft model.",
author = "Nordmaj, {Mie A.} and Roberts, {Morgan E.} and Sachse, {Emilie S.} and Robert Dagil and Andersen, {Anne Poder} and Nanna Skeltved and Grunddal, {Kaare V.} and Erdoğan, {Sayit Mahmut} and Swati Choudhary and Tobias Gustavsson and {\O}rum-madsen, {Maj Sofie} and Igor Moskalev and Weihua Tian and Zhang Yang and Clausen, {Thomas M.} and Theander, {Thor G.} and Mads Daugaard and Nielsen, {Morten A.} and Ali Salanti",
year = "2021",
doi = "10.1038/s41419-021-03611-0",
language = "English",
volume = "12",
journal = "Cell Death & Disease",
issn = "2041-4889",
publisher = "nature publishing group",
number = "4",

}

RIS

TY - JOUR

T1 - Development of a bispecific immune engager using a recombinant malaria protein

AU - Nordmaj, Mie A.

AU - Roberts, Morgan E.

AU - Sachse, Emilie S.

AU - Dagil, Robert

AU - Andersen, Anne Poder

AU - Skeltved, Nanna

AU - Grunddal, Kaare V.

AU - Erdoğan, Sayit Mahmut

AU - Choudhary, Swati

AU - Gustavsson, Tobias

AU - Ørum-madsen, Maj Sofie

AU - Moskalev, Igor

AU - Tian, Weihua

AU - Yang, Zhang

AU - Clausen, Thomas M.

AU - Theander, Thor G.

AU - Daugaard, Mads

AU - Nielsen, Morten A.

AU - Salanti, Ali

PY - 2021

Y1 - 2021

N2 - As an immune evasion and survival strategy, the Plasmodium falciparum malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohydrate abundantly and exclusively present in the placenta. Cancer cells were found to share the same expression of this distinct carbohydrate, termed oncofetal chondroitin sulfate on their surface. In this study we have used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. Conjugation of these two proteins resulted in a single functional moiety that induced immune mediated killing of a broad range of cancer cells in vitro and facilitated tumor arrest in an orthotopic bladder cancer xenograft model.

AB - As an immune evasion and survival strategy, the Plasmodium falciparum malaria parasite has evolved a protein named VAR2CSA. This protein mediates sequestration of infected red blood cells in the placenta through the interaction with a unique carbohydrate abundantly and exclusively present in the placenta. Cancer cells were found to share the same expression of this distinct carbohydrate, termed oncofetal chondroitin sulfate on their surface. In this study we have used a protein conjugation system to produce a bispecific immune engager, V-aCD3, based on recombinant VAR2CSA as the cancer targeting moiety and an anti-CD3 single-chain variable fragment linked to a single-chain Fc as the immune engager. Conjugation of these two proteins resulted in a single functional moiety that induced immune mediated killing of a broad range of cancer cells in vitro and facilitated tumor arrest in an orthotopic bladder cancer xenograft model.

U2 - 10.1038/s41419-021-03611-0

DO - 10.1038/s41419-021-03611-0

M3 - Journal article

C2 - 33824272

VL - 12

JO - Cell Death & Disease

JF - Cell Death & Disease

SN - 2041-4889

IS - 4

M1 - 353

ER -

ID: 259571723